Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04095793 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study, sponsored by Theravance Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
NCT04095793 is a Phase 3 study that was terminated before completion, run by Theravance Biopharma. The registered enrollment target is 110 participants.
The verdict
NCT04095793, a Phase 3 study, was terminated before completion, sponsored by Theravance Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
Study Summary
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
Interventions
- DRUG ampreloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2019-09-19 |
| Est. Completion | 2021-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04095793
The ClinicalTrials.gov registry entry for NCT04095793 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ampreloxetine is the first listed.
NCT04095793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04095793 about?
NCT04095793 is a clinical study titled "Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure". A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
What is the current status of trial NCT04095793?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2019-09-19. Estimated completion is 2021-11-12.
What interventions are being tested in trial NCT04095793?
The interventions under investigation include: ampreloxetine (DRUG).
Who is sponsoring clinical trial NCT04095793?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.